Rofact (Rifampin) drug shortage in Canada: Nitrosamine impurity
In plain language
This recall involves Rofact (Rifampin) sold in Canada. It's being recalled because some lots contain slightly higher than acceptable levels of a nitrosamine impurity. Do not stop taking the product without first discussing treatment options with your healthcare provider.
What to do
- Do not stop taking your rifampin.
- Discuss treatment options with your healthcare provider.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Specific affected products are listed in the official notice.
Why this matters
Potential increased cancer risk from nitrosamine impurity
Do I have this product?
This recall applies to specific products. Details are listed in the official notice.
Frequently Asked Questions
Why was this product recalled?
Potential increased cancer risk from nitrosamine impurity
What should consumers do?
Do not stop taking your rifampin. Discuss treatment options with your healthcare provider.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Potential increased cancer risk from nitrosamine impurity
When was this product recalled?
This product was recalled on March 15, 2020.
Is the Rofact brand affected by this recall?
Yes, Rofact products are affected by this recall. This recall involves Rofact (Rifampin) sold in Canada. It's being recalled because some lots contain slightly higher than acceptable levels of a nitrosamine impurity. Do not stop taking the product without first discussing treatment options with your healthcare provider.